Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up

Leukemia

Volumn 17, Issue 2, 2003, Pages 328-333

  Yetgin, S ^a   Tuncer, M A ^a   Cetin M ^a   Gumruk F ^a   Yenicesu, I ^a   Tunc B ^a   Oner A F ^a   Toksoy, H ^a   Koc A ^a   Aslan, D ^a   Ozyurek E ^a   Olcay, L ^a   Atahan, L ^a   Tuncbilek E ^a   Gurgey A ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Children; Event free survival (EFS); High dose methyprednisolone (HDMP)

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GLUCOCORTICOID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PREDNOL L; TENIPOSIDE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; ARTICLE; BEHAVIOR DISORDER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATOMEGALY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFANT; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 0037328537     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402673     Document Type: Article

References (36)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
2. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-1630.
3. Pui CH. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol 1998; 5: 292-301.
4. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997 80: 1717-1726.
5. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449-1463.
6. Manera R, Ramirez I, Mullins J, Pinkel D. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. Leukemia 2000; 14: 1354-1361.
7. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790-794.
8. Thompson EB. Apoptosis and steroid hormones. Mol Endocrinol 1994; 8: 665-673.
9. Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma 1994; 15: 363-374.
10. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-344.
11. Gustafsson JA, Carlstedt-Duke J, Poellinger L, Okret S, Wikstrom AC, Bronnegard M, Gillner M, Deng Y, Fuxe K, Cintra A. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987; 8: 185-234.
12. Gehring U. Genetics of glucocorticoid receptors (review). Mol Cell Endocrinol 1986; 48: 89-96.
13. Özsoylu S. High dose intravenous methylprednisolone in hematologic disorders. Hematol Rev 1990; 4: 197-207.
14. Shamson E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med 1962; 266: 1354-1358.
15. Ryalls MR, Pinkerton CR, Meller ST, Talbot D, McElwain TJ. High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1992; 20: 119-123.
16. Hiçsönmez G, Onat N, Albayrak D, Yetgin S, Özsoylu S. Acceleration of leukocyte recovery by administration of short-course high-dose methylprednisolone in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1991; 8: 193-197.
17. Özbek N, Yetgin S, Tuncer M. Effects of G-CSF and high-dose methylprednisolone on peripheral stem cells, serum IL-3 levels and hematological parameters in acute lymphoblastic leukemia patients with neutropenia: a pilot study. Leuk Res 2000; 24: 55-58.
18. Hiçsönmez G, Özsoylu S, Onat N, Zamani VP, Gümrük F, Tuncer M. High dose methylprednisolone in resistant and relapsed children with acute lymphoblastic leukemia. Med Pediatr Oncol 1994; 22: 68-69.
19. Hiçsönmez G, Gümrük F, Zamani PV, Tuncer MA, Yetgin S, Gürgey A, Atahan L, Özsoylu S. High-dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting features. Eur J Haematol 1997; 58: 26-31.
20. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
21. Yetgin S, Gürgey A, Tuncer AM, Cetin M, Özbek N, Sayli T, Güler E, Kara A, Olcay L, Duru F, Gümrük F, Atahan L, Tunçbilek E. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leuk Res 1998; 22: 485-493.
22. Spurbeck JL, Carlson RO, Allen JE, Dewald GW. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet 1988; 32: 59-66.
23. Mitelman F (ed.). An International System for Human Genetic Nomenclature. Karger: Basel, 1995.
24. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
25. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, and Sallan SE. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001; 19: 1040-1046.
26. Çetin M, Hiçsönmez G, Tuncer AM, Kansu E, Canpinar H. The effect of short-course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia. Exp Hematol 1996; 24: 1191-1194.
27. Thomson EB, Harmon JB, Zawydiwski R. Corticosteroid effects on an ALL cell live: a model for understanding steroid therapy. In: Murphy SB, Gilbert JR (eds). Leukemia Research. Advances in Cell Biology and Treatment. Elseiver Science: New York, NY, 1983, pp 157-169.
28. Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: Pediatric Oncology Group Study. Cancer Res 1985; 45: 6482-6486.
29. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 780-790.
30. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990; 62: 1189-1204.
31. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996; 383: 726-728.
32. Hiçsönmez G, Özsoylu S, Yetgin S, Zamani V, Gürgey A, Atahan I. Prognosis in 262 Turkish children with acute lymphocytic leukemia. Turk J Pediatr 1982; 24: 159-167.
33. Pui C-H, Boyett JM, Rivera GK, Hancock ML,Sandlund JT, Riberio RC, Rubnitz JE, Behm FG, Raimondi SC, Gajjar A, Razzouk B, Campana D, Kun LE, Relling Mvand Evans WE. Long-term results of total therapy studies 11,12 and 13A for children with acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
34. Walters TR, Bushore M, Simone J. Poor prognosis in Negro children with acute lymphocytic leukemia. Cancer 1972; 29: 210-214.
35. Hiçsönmez G, Özsoylu S, Yetgin S, Zamani V, Gürgey A. Poor prognosis of childhood acute lymphoblastic leukaemia. Br Med J 1983; 286: 1437.
36. Çetin M, Yetgin S, Kara A, Tuncer AM, Günay M, Gümrük F, Gürgey A. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med 1994; 25: 219-229.